Animal
What makes SLU-PP-915 worth investigating alongside 332?
Demonstrated findings
A chemically distinct ERR agonist showed oral activity and enhanced aerobic exercise capacity in preclinical experiments.
What might this mean? · interpretation
Improved delivery makes sustained ERR modulation an interesting research possibility.
What might this mean, and what would change the interpretation?
Preclinical oral activity does not establish human oral exposure or clinical benefit, and does not make 915 interchangeable with 332.
What would clarify this: Human exposure and tolerability studies followed by functional endpoints.
Mechanism to possible human relevance
- Working explanation
- Oral preclinical activity could make sustained ERR modulation easier to investigate.
- Possible human implication, hypothesis
- Oral exposure and exercise-capacity endpoints are plausible human research questions.
- Evidence that would support it
- Demonstrated human exposure, acceptable tolerability and replicated functional improvement.
- Evidence that would challenge it
- Poor human exposure, limiting adverse effects, or no functional response despite target engagement.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
Publication identity and preclinical findings checked against PMID 41421047. Full text was unavailable.